Design Therapeutics, Inc.
DSGN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001807120
Insider trades, last 90 days
None
- No open-market purchases or sales were filed in the last 90 days.
13F holders, Q2 2026
136
- +11 vs. Q1 2026
- Total value $626.45M
Superinvestors holding DSGN
0
- None of the superinvestors held DSGN at the end of Q2 2026.
Price chart
Latest insider trades
View all: Latest insider tradesOpen-market purchases and sales by DSGN insiders, newest first.
| Filed (ET) | Trade date | Insider | Transaction | Shares | Avg price | Value | Shares after | Holding change | Filing |
|---|---|---|---|---|---|---|---|---|---|
| Aug 14, 2025 | Aug 13, 2025 | William ArsaniDirector | SSaleCommon Stock | −562.63K | $5.25 | −$2.95M | 1M | −36.0% | SEC |
| Dec 19, 2024 | Dec 18, 2024 | Prasad DeepaDirector | SSaleCommon Stock | −3.81K | $6.27 | −$23.86K | 20K | −16.0% | SEC |
| Aug 12, 2024 | Aug 9, 2024 | William ArsaniDirector | SSaleCommon Stock | −814.87K | $4.25 | −$3.46M | 0 | −100.0% | SEC |
| Mar 25, 2024 | Mar 22 – Mar 25, 2024 | Schmid John P.Director | PPurchaseCommon Stock | +26.97K | $3.6993 | +$99.75K | 26.97K | New position | SEC |
| Mar 25, 2024 | Mar 25, 2024 | Behanna HeatherDirector | PPurchaseCommon Stock | +1.3K | $3.74 | +$4.86K | 1.3K | New position | SEC |
Top 5 13F holders, Q2 2026
View all: Top 5 13F holders, Q2 2026The largest institutional positions in DSGN at the end of Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| SR ONE CAPITAL MANAGEMENT, LP | 6,526,476 | $94.44M | 9.09% | 00.0% | Unchanged |
| Logos Global Management LP | 3,000,000 | $43.41M | 1.87% | +1,050,000+53.8% | Added |
| BAKER BROS. ADVISORS LP | 2,678,430 | $38.76M | 0.19% | +92,452+3.6% | Added |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 2,661,115 | $38.51M | 0.22% | +916,128+52.5% | Added |
| BlackRock, Inc. | 2,660,024 | $38.49M | 0.00% | +526,260+24.7% | Added |